VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced 13 podium and poster presentations during the European Society of Cataract and Refractive Surgery (ESCRS) annual meeting, which will take place in Vienna Sept.

安大略省沃恩-（商业线）-博士伦公司（NYSE/TSX:BLCO）是一家领先的全球眼保健公司，致力于帮助人们看到更好的生活，今天宣布13次讲台和海报展示欧洲白内障和屈光手术学会（ESCRS）年会，将于9月在维也纳举行。

8-12, 2023..

8-12, 2023..

The presentations will include:

演示文稿将包括：

A three-year analysis of the superonasal minimally invasive micro sclerostomy (MIMS) surgical treatment for open angle glaucoma*

超鼻腔微创微创微硬化（MIMS）手术治疗开角型青光眼的三年分析*

Interim results of surgical procedures that used MINT™ (Minimally Invasive Nasal Trabeculostomy) in open angle glaucoma patients

使用MINT的外科手术的中期结果™ 开角型青光眼患者的微创鼻小梁切除术

An evaluation of visual outcomes in patients with complex corneas who were implanted with the IC-8 Apthera intraocular lens (IOL)

评估植入IC-8 Apthera人工晶状体（IOL）的复杂角膜患者的视力结果

Clinical outcomes of the LuxSmart™ toric IOL

LuxSmart的临床结果™ toric IOL

Safety and performance results of the enVista® ENVY, an investigational premium IOL

enVista®嫉妒（一种研究性优质人工晶状体）的安全性和性能结果

Refractive outcomes of a low 0.90 diameter cylinder for the investigational enVista Toric IOL.

用于研究环境IOL的低0.90直径圆柱体的屈光结果。

Bausch + Lomb will also host several educational and networking events during the meeting. Educational events will include a MIMS masterclass and a panel of distinguished physicians who will provide insights from their firsthand clinical experience using the company’s newly launched SeeLuma Fully Digital Surgical Visualization Platform.

博士伦还将在会议期间举办多项教育和网络活动。教育活动将包括MIMS硕士课程和一组杰出医生，他们将使用公司新推出的SeeLuma全数字外科可视化平台，从他们的第一手临床经验中提供见解。

Other presentations featuring the company’s latest surgical technology will take place in the Bausch + Lomb booth, and Bausch + Lomb will host a Lift Off Celebration event to mark its 170th anniversary..

其他以该公司最新手术技术为特色的演讲将在博士伦+伦布展台上举行，博士伦+伦布将举办庆祝活动，以纪念其170周年。。

Following is the list of key scientific podium and e-poster presentations, as well as details for the featured educational events:

以下是关键科学讲台和电子海报演示文稿列表，以及特色教育活动的详细信息：

Podium Presentations

讲台演示

“Evaluating the Range of Vision with a Small Aperture IOL in Patients Previously Treated with a Monofocal IOL in the Other Eye.” S. Bafna et al.

“使用小孔径IOL评估先前在另一只眼中使用单焦点IOL治疗的患者的视力范围。”S.Bafna等。

“Evaluation of the Safety and Performance of a Novel One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens: Results from a Prospective, Multicentre Clinical Trial.” P. Harasymowycz et al.

“评估新型单件式疏水丙烯酸三焦点人工晶状体的安全性和性能：一项前瞻性多中心临床试验的结果。”P.Harasymowycz et al。

“Evaluation of Visual Outcomes in Patients with Complex Corneas Implanted with the IC-8 IOL.” J. Mehta et al.

“评估植入IC-8 IOL的复杂角膜患者的视力结果。”J.Mehta等。

“Prospective Study of Small Aperture IOL Implantation in Eyes with Previous Refractive Procedures.” R.E. Ang et al.

“用先前的屈光手术对眼睛进行小孔径IOL植入的前瞻性研究”，R.E.Ang et al。

Poster Presentations

墙报交流

“Clinical Outcomes After Bilateral Implantation of The Enhanced Depth of Focus LuxSmart Intraocular Lenses.” W. Lubiński et al

“双侧植入增强焦深LuxSmart人工晶状体后的临床结果。”W.Lubiński等

“Clinical Outcomes of a Toric Extended Range of Vision Intraocular Lens Based on the Combination of Fourth- and Sixth-Order Spherical.” R. Ruiz-Mesa et al.

“基于四阶和六阶球形组合的环形扩展视野人工晶状体的临床结果。”R.Ruiz-Mesa等。

“Comparison of Two Extended Range of Focus Intraocular Lenses: Vivity Vs. Luxsmart.” J. Hugues et al.

“两种扩展聚焦人工晶状体的比较：Vivity与Luxsmart。”J.Hugues等。

“Retinal Visualization in a Small Aperture IOL Treated Eyes.” M. Blecher et al.

“在小孔径IOL处理过的眼睛中进行视网膜可视化。”M.Blecher等。

“Visual Performance of Ultra-Low Cylinder Powered (0,90) Toric IOL Compared to Non-Toric.” A. Muzychuk et al.

“与非环形相比，超低圆柱动力（0,90）环形IOL的视觉性能。”A.Muzychuk等。

“Minimally Invasive Micro Sclerostomy: 3 Years Follow Ups.” L. Voskanyan et al.

“微创微硬化造口术：3年随访。”L.Voskanyan等。

“Trabeculostomy as a New Effective Surgery for Glaucoma.” L. Voskanyan et al.

“小梁切除术作为青光眼的一种新的有效手术。”L.Voskanyan等。

“Acufocus IC-8 Implantation During Cataract Surgery in Irregular Corneas.” C. Hubert et al

“Acufocus IC-8在不规则角膜白内障手术中的植入。”C.Hubert等

“Visual Outcomes Following Implantation of Small Aperture Intraocular Lens in Patients with Irregular Corneas.” U. Bhatt

“角膜不规则患者植入小孔径人工晶状体后的视力结果。”U.Bhatt

Featured Educational Events

特色教育活动

Friday, September 8

周五，9月8日

“MIMS Masterclass”

“MIMS Masterclass”

5:30-7:30 p.m. CEST at Palais Palffy, Josefsplatz 6, Vienna

欧洲东部时间下午5:30-7:30，地点：维也纳Josefsplaz 6 Palais Palffy

Professor Anselm Jünemann, Dr. Imran Masood, Professor Luis Pablo and Dr. Lilit Voskanyan will present their experiences with the MIMS surgical treatment for open angle glaucoma.

AnselmJünemann教授，Imran Masood博士，Luis Pablo教授和Lilit Voskanyan博士将介绍他们在开角型青光眼MIMS手术治疗方面的经验。

Saturday, September 9

9月9日星期六

“New Dimensions in Visualization: Changing the Way You Look & Your Patients See”

“可视化的新维度：改变你的外表和病人看到的方式”

1:00-2:00 p.m. CEST at Messe Wien Exhibition & Congress Centre, Room A7, Vienna

1： 00-2:00下午CEST在维也纳A7室Messe Wien展览和会议中心

Professor Burkhard Dick will lead an engaging conversation with an international panel of surgeons, including Drs. Robert Ang, Alain Saad and Adam Muzychuk, who will share their surgical experiences using the IC-8 Apthera IOL, SeeLuma Fully Digital Visualization Platform and Stellaris Elite™ Phacoemulsification System, respectively..

Burkhard Dick教授将领导与国际外科医生小组的互动，包括Robert Ang博士，Alain Saad博士和Adam Muzychuk博士，他们将使用IC-8 Apthera IOL，SeeLuma Full Digital Visualization Platform和Stellaris Elite分享他们的手术经验™ 超声乳化系统。。

Saturday, September 9 and Sunday, September 10

9月9日星期六和9月10日星期日

'Meet the Expert”

“会见专家”

9:30 a.m.-4:30 p.m. CEST at Messe Wien Exhibition & Congress Centre, booth #B203, Vienna

9： 上午30点至下午4点30分，维也纳B203展位Messe Wien展览与大会中心CEST

Surgeons will share their surgical experiences using the LuxSmart™ IOL, IC-8 Apthera IOL, SeeLuma Fully Digital Visualization Platform, Stellaris Elite and the refractive SUPRACOR™ and transepi PRK procedures.

外科医生将使用LuxSmart分享他们的手术经验™ IOL，IC-8 Apthera IOL，SeeLuma全数字可视化平台，Stellaris Elite和屈光SUPRACOR™ 和transepi PRK程序。

Sunday, September 10

星期日，9月10日

“Lift Off Celebration”

“起飞庆祝”

6:30-10:30 p.m. CEST at Palais Ferstel, Strauchgasse 4, Vienna

欧洲东部时间下午6:30-10:30，维也纳斯特劳加塞4号费尔斯泰尔宫

ESCRS attendees are invited to celebrate Bausch + Lomb’s 170th anniversary.

ESCRS与会者应邀庆祝博士伦170周年。

For more information, visit https://events.bauschsurgical.eu/escrs/.

欲了解更多信息，请访问https://events.bauschsurgical.eu/escrs/.

About Bausch + Lomb

关于Bausch

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.

博士伦致力于保护和增强世界各地数百万人的视力礼物-从出生到生命的每个阶段。其全面的400多种产品组合包括隐形眼镜，镜片护理产品，眼保健产品，眼科药物，非处方产品以及眼科手术器械和器械。

Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram..

博士伦成立于1853年，拥有重要的全球研发，制造和商业足迹，约有13000名员工，并在近100个国家/地区设有。博士伦总部设在安大略省沃恩市，公司总部设在新泽西州布里奇沃特。欲了解更多信息，请访问www.bausch.com并在Twitter，LinkedIn，Facebook和Instagram上与我们联系。。

Forward-looking Statements

前瞻性声明

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions.

该新闻稿可能包含前瞻性陈述，通常可以通过使用“预期”，“希望”，“期望”，“意图”，“计划”，“应该”，“可以”，“将会”，“可以”相信，“估计”，“潜力”，“目标”或“继续”以及变体或类似表达。

These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S.

这些声明基于当前对管理层的期望和信念，并且存在某些风险和不确定性，可能导致实际结果与前瞻性声明中描述的结果大不相同。这些风险和不确定性包括但不限于博士伦与美国的文件中讨论的风险和不确定性。

Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law..

证券交易委员会和加拿大证券管理员，这些因素通过引用并入本文。提醒读者不要过分依赖这些前瞻性陈述。这些前瞻性声明仅在本协议签署之日起生效。除非法律要求，否则博士伦不承担更新任何这些前瞻性陈述的义务，以反映本新闻发布之日以后的事件或情况或反映实际结果。。

*Bausch + Lomb exclusively distributes MIMS in Europe through a strategic agreement with Sanoculis.

*博士伦通过与Sanoculis的战略协议专门在欧洲分销MIM。

© 2023 Bausch + Lomb.

© 2023 Bausch Lomb。